[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1990

Second Thoughts on 3,4-Methylenedioxymethamphetamine (MDMA) Neurotoxicity-Reply

Arch Gen Psychiatry. 1990;47(3):289. doi:10.1001/archpsyc.1990.01810150089015

In Reply.—  Grob et al raise some valid points regarding the methodological limitations of our findings, which we ourselves had attempted to acknowledge, both in the "Comment" section and in our characterization of our results as "preliminary observations." There are, however, several other issues raised by Grob et al on which we offer the following comments:1. Urine toxicology by enzyme immunoassay (EMIT) was obtained on all subjects on the morning of the intravenous L-tryptophan test, immediately prior to beginning the test. Although inadvertently omitted from the final draft of the article, these screens revealed no evidence of recent use of psychoactive drugs. However, most of our subjects did have a past history of use of illicit psychoactive drugs; as Grob et al imply, we cannot state with certainty that use of these other drugs did not account for or contribute to the altered responses to L-tryptophan. The fact is,